Tolerance and Effectiveness of C14 on HPV Infection

Launched by MGB PHARMA · Nov 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called C14 to see if it can help women with persistent high-risk HPV infections, which can lead to certain cancers, including cervical cancer. The main goals are to find out if C14 can lower the amount of HPV virus in the body and if it can help treat early changes in cervical cells that could become cancerous. To do this, researchers will compare C14 to a placebo, which looks the same but doesn’t contain any active medicine.

Women who may be eligible to participate are those who are at least 30 years old, sexually active, and can give their consent to be part of the study. However, pregnant or breastfeeding women, those who have had previous cervical surgery, or anyone with certain medical conditions will not be able to join. Participants will receive C14 or the placebo for four months, with treatments given twice a day. They will visit the clinic every two weeks for check-ups and are asked to keep a diary of their symptoms and appointments. This trial is not yet recruiting participants, but it's an important step toward finding new options for managing HPV-related health issues.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • sexually-active women
• • aged at least 30 years old
• • who will give their informed consent to participate in the study.
• Exclusion Criteria:
• • Pregnant
• • breastfeeding and post-partum women will not be accepted in the study.
• • previous cervical surgery, medical history of any severe diseases, intake or application of other antivirals
• • known or suspected allergic or adverse response to the investigational product or its components
• • women who are unable to follow the study protocol.